Benzinga’s Top Pre-Market Gainers (SCLN, SPPI, CDII, CRUS, JADE, NVAX, STXS)

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) increased 9.75% to $3.04 after SciClone Pharmaceuticals and Sigma-Tau S.p.A. announced positive preliminary results in a clinical study examining ZADAXIN. SciClone Pharmaceuticals closed at $2.77 in the last trading session. The 52 week trading range for SCLN is $0.78 -$5.33.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) climbed 5.64% to $4.87 after Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone have achieved their enrollment targets. In the last trading session, SPPI closed at $4.61. SPPI surged over 205% in the last year.

China Direct Industries, Inc. (NASDAQ: CDII) jumped 8.88% to $2.33 in the pre-market session. The 52-week trading range for CDII is $0.91 - $2.48. China Direct Industries closed at $2.14 in the previous trading session. In the last six months, CDII gained over 50%.

Cirrus Logic, Inc. (NASDAQ: CRUS) moved up 11.63% to $7.39. Yesterday, Cirrus Logic announced that for 3Q2010, it expects net revenue to be up 49% y-o-y to approximately $65 million. Cirrus previously expected third quarter net revenue to be in the range of $58 million to $62 million. CRUS closed at $6.62 in the last trading session. CRUS gained over 60% in the last six months.

LJ International, Inc. (NASDAQ: JADE) surged 5.86% to $3.07 in the pre-market session. The 52-week trading range for JADE is $0.47 - $3.98. Yesterday, JADE closed at $2.90. In the last six months, LJ International moved up 61%.

Novavax, Inc. (NASDAQ: NVAX) climbed 4.30% to $3.15 after Novavax today announced that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats. The 52 week trading range for NVAX is $0.52 -$7.79. In the last six months, NVAX gained over 17%.

Stereotaxis, Inc. (NASDAQ: STXS) increased 9.34% to $4.45 in the pre-market session after Stereotaxis today announced that the Celsius® RMT ThermoCool® catheter has been approved by the U.S. Food and Drug Administration for the treatment of Type 1 atrial flutter. In the last trading session, STXS closed at $4.07. In the last six months, STXS gained over 19%.